Skip to content

Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure

Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05861843
Acronym
CRAVE
Enrollment
61
Registered
2023-05-17
Start date
2023-09-23
Completion date
2024-06-30
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder

Brief summary

Alcohol use disorder (AUD) is a burdensome clinical disorder with high relapse rates. Virtual Reality (VR)-based therapeutic and diagnostic approaches have received increasing attention in the treatment of AUD but evidence on the induction of craving via VR scenarios is still needed. Craving for alcohol is associated with psychological and physiological responses. This single-arm clinical study will be conducted including n=60 patients with AUD. Using a head-mounted display (HMD), patients will be confronted with three different VR scenarios (neutral vs. two target situations) while heart rate, heart rate variability (HRV), pupillometry and electrodermal activity (EDA) will be measured continuously. Subjective craving levels will be assessed pre-/during/post-exposure to each VR scenario.

Interventions

DIAGNOSTIC_TESTVirtual Reality-based cue exposure paradigm

Virtual Reality (VR) cue exposure to alcohol-associated cues using head-mounted displays (HMD)

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* age: 18-65 years * diagnosis of alcohol dependence according to ICD-10 (F10.2) * completed in-patient withdrawal treatment during the last 3 months * history of alcohol craving, confirmed via craving questionnaires * able to provide written informed consent

Exclusion criteria

* substance dependence other than alcohol and nicotine * current alcohol intoxication (randomly tested via measurement of breath alcohol concentration) * unable to understand the study information, consent form or principles of the study * abstinence for less than 7 days or on-going consumption of alcohol * severe neuropsychiatric disorder, e.g. schizophrenia spectrum disorders, bipolar affective disorder or substantial cognitive impairment * serious illnesses influencing brain-/heart-function with influence on physiological study parameters. * acute suicidality (or acute endangerment of others) * concurrent pharmacological treatment targeting AUD (i.e. benzodiazepines) or craving (i.e. acamprosate, disulfiram, naltrexone, nalmefene) and further medication significantly influencing heart frequency.

Design outcomes

Primary

MeasureTime frameDescription
change in psychophysiological craving levels (heart rate) elicited by alcohol-associated cues20-30 min VR exposureChanges in craving levels measured continuously by heart rate (bpm = beats per minute) during VR-exposure to alcohol-associated cues compared to neutral cues.
change in psychophysiological craving levels (electrodermal activity) elicited by alcohol-associated cues20-30 min VR exposureChanges in craving levels measured continuously by electrodermal activity (micro-Siemens) during VR-exposure to alcohol-associated cues compared to neutral cues.
change in psychophysiological craving levels elicited by alcohol-associated cues20-30 min VR exposureChanges in craving levels measured continuously by pupillometry (pupil dilation in mm) during VR-exposure to alcohol-associated cues compared to neutral cues.
change in subjective craving levels elicited by alcohol-associated cues20-30 min VR exposureChanges in craving levels measured by subjective parameters (visual analogue scale = VAS, scale 0-100) before, during and after VR-exposure to alcohol-associated cues compared to neutral cues
change in psychophysiological craving levels (heart rate variability) elicited by alcohol-associated cues20-30 min VR exposureChanges in craving levels measured continuously by heart rate variability (ms) during VR-exposure to alcohol-associated cues compared to neutral cues.

Secondary

MeasureTime frameDescription
development of subjective craving levels post-exposure3 hours after VR-exposurechanges of subjective craving (VAS) over the following 3 hours after VR-exposure
context-related change in craving levels20-30 minutes VR Exposurechanges in subjective and objective craving levels compared between the two VR-scenarios bar vs. living room

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 28, 2026